Millennium Medical PublishingHighlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020

This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).

American Society of Clinical OncologyPlaying with Dynamite? A Cautious Assessment of TNT

In this article from the Journal of Clinical Oncology, the authors suggest the need for caution and well-conducted trials to systematically address the question of total neoadjuvant therapy (TNT) in rectal cancer, which can lead to overtreatment and unnecessary toxicity without a proven benefit. Despite some of its theoretical advantages, declaring TNT a new standard […]